NASDAQ : RNXT

RenovoRx, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.49 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 67.24M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Details

NameRenovoRx, Inc.
SectorHealthcare
IndustryBiotechnology
Employees17
Founded2012
Ipo Date2021-08-26
CeoShaun Bagai
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price9.00
IsinUS75989R1077
Cusip75989R107
Cik1574094
Sic3841
Stock TypeCommon Stock

Key executives

NameTitle
Shaun R. BagaiChief Executive Officer, Secretary and Director
Dr. Ramtin Agah M.D.Founder, Executive Chairman and Chief Medical Officer
Ronald B. Kocak CPA, CGMAVice President of Finance and Controller
Mark VollChief Financial Officer and Principal Accounting Officer
Tom KellyVice President of Quality and Operations
Phil StoctonVice President of Sales and Market Development
Leesa GentryChief Clinical Officer

Contact

Address2570 West El Camino Real, Suite 320, Mountain View, California 94040, United States
Phone650 284 4433
Websitehttps://renovorx.com